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Abstract 
 
Background:  The PARAMEDIC cluster randomised trial evaluated the LUCAS mechanical chest 
compression device, and did not find evidence that use of mechanical chest compression led to an 
improvement in survival at 30 days.  This paper reports patient outcomes from admission to hospital 
to 12 months after randomisation.  
Methods: Information about hospital length of stay and intensive care management were obtained 
through linkage with Hospital Episode Statistics and the Intensive Care National Audit and Research 
Centre.  Patients surviving to hospital discharge were approached to complete questionnaires (SF-
12v2, EQ-5D, MMSE, HADS and PTSD-CL) at 90 days and 12 months.  The study is registered with 
Current Controlled Trials, number ISRCTN08233942. 
Results: 377 patients in the LUCAS arm and 658 patients in the manual chest compression were 
admitted to hospital. Hospital and intensive care length of stay were similar.  Long term follow-up 
assessments were limited by poor response rates (53.7% at 3 months and 55.6% at 12 months).  
Follow-up rates were lower in those with worse neurological function. Among respondents, long 
term health related quality of life outcomes and emotional well-being was similar between groups.  
Cognitive function, measured by MMSE, was marginally lower in the LUCAS arm mean 26.9(SD 3.7) 
compared to control mean 28.0(SD 2.3), adjusted mean difference -1.5 (95% CI -2.6 to – 0.4). 
Conclusion: There were no clinically important differences identified in outcomes at long term 
follow-up between those allocated to the mechanical chest compression compared to those 
receiving manual chest compression.  
Word count: 241 
 
4 
 
 
  
5 
 
 
 
Background 
 
High quality chest compressions are associated with improved outcomes from cardiac arrest.1-3  
However, maintaining high quality chest compressions is physically challenging4 so the concept of a 
mechanical chest compression device, which automates the process of chest compressions, is 
attractive.5   The out of hospital, randomised assessment of a mechanical chest compression device 
(PARAMEDIC) trial was a cluster randomised open-label clinical effectiveness trial which compared 
mechanical chest compressions, delivered by the LUCAS-2 device (Physiocontrol, Lund) to manual 
chest compressions (control) delivered by National Health Service ambulance personnel.  The initial 
findings of the trial have been previously reported.6,7 The study did not find an advantage to LUCAS 
chest compressions for the rate of return of spontaneous circulation, (LUCAS 32% vs control 31%, 
adjusted OR (adjusted odds ratio ((aOR)) 1.0 (95% confidence interval 0.9–1.1)), survived event 
(LUCAS 23% vs control 23%, aOR 1.0 (0.8–1.1)) or 30-day survival, (LUCAS 6% vs control 7%, aOR 0.9 
(0.6–1.2)). However slightly more patients in the LUCAS arm had an unfavourable neurological 
outcome compared to those receiving manual chest compressions (5% vs 6% respectively, aOR 0.7 
(0.5-1.0)).  
Most previous randomised controlled trials in out of hospital cardiac arrest have focused on short 
term outcomes (return of spontaneous circulation, survival to discharge).8 Gross neurological 
function is usually measured with tools such as Cerebral Performance Score (CPC) and modified 
Rankin Scale (mRS). However, these tools may be insensitive to some of the more subtle, yet 
important longer term neurocognitive and functional impairments experienced by survivors of 
cardiac arrest.9-11  The spectrum of impairment of health related quality of life following cardiac 
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arrest includes memory and cognitive dysfunction, affective disorders and post-traumatic stress 
disorder (PTSD).10,12  
This paper extends the findings from the original trial by reporting on longer term outcomes amongst 
those who survived beyond hospital discharge.  In addition, through linkage with national 
administrative data, hospital and intensive care unit length of stay, mode of death and organ donation 
rates after death are presented. 
 
Data and Methods 
 
The PARAMEDIC trial examined the effectiveness of LUCAS-2, a mechanical cardiopulmonary 
resuscitation (CPR) device, in 4471 out-of-hospital cardiac arrest patients compared to standard 
manual CPR. The study was designed as a cluster randomised trial, whereby the ambulance vehicles 
were randomised to carry the LUCAS CPR device (intervention) or not (control). Full details of study 
design are presented in the trial protocol, which has been published previously.13  In brief, adults 
who sustained out of hospital cardiac arrest, where resuscitation was attempted by ambulance 
personnel and were attended by a trial vehicle were eligible for inclusion.  Those with cardiac arrest 
caused by trauma or with known or clinically apparent pregnancy were excluded.  The primary 
outcome (30-day survival) and some of the secondary outcomes (survived event, survival to 
discharge, neurological status and survival at 3 and 12 months) have been previously reported).6 This 
study reports the pre-defined secondary outcomes of health-related quality of life, cognitive 
function, anxiety and depression, post-traumatic stress, hospital and intensive care length of stay.  
These outcomes are also presented in the in-depth trial report published as a Heath Technology 
Assessment Monograph.7 Post-hoc additional analyses included reporting intensive care and hospital 
free days, mode of death and organ donation rates after death.    
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Linkage with Health & Social Care Information Centre (HSCIC) and the Intensive Care National Audit 
Research Centre (ICNARC) 
The UK Health & Social Care Information Centre (HSCIC) and Intensive Care National Audit & 
Research Centre (ICNARC), were contacted for the hospital data of patients who survived long 
enough to be admitted to hospital. This analysis was based on the combination of the original trial, 
and linked HSCIC and ICNARC data. Approvals were obtained from the Coventry and Warwickshire 
Research Ethics Committee, HSCIC Data Access Advisory Group (DAAG) and ICNARC.  
The trial recruitment was run between April 15, 2010, and June 10, 2013. Patient flow was shown in 
the CONSORT diagram (Figure 1). Of the 4471 randomised patients, 2695 (951 or 35.3% in LUCAS) 
were not known to be deceased at emergency department. No patient recruited after March 2013 
were linked to HSCIC because the 2013-14 data were not available before our linkage application. 
Therefore, 2398 (843 or 35.2% in LUCAS) were considered eligible for linkage.  
Information on hospital length of stay was provided by Hospital Episodes Statistics (HES) admitted 
and A&E datasets.  Approximately 40-50% of patients admitted to hospital after cardiac arrest are 
admitted to intensive care.14  ICNARC provided data for intensive care duration, survival, 
temperature management, organ donation and withholding of treatment information.  
HES admitted patient care data were used to calculate hospital length of stay and survival to hospital 
discharge, with supplementary discharge and death data collected in the trial. Hospital length of stay 
was defined as days between cardiac arrest and discharge from or death in hospital. ICU length of 
stay was defined as days between ICU admission and discharge from or death in ICU. Patients who 
did not achieve sustained ROSC at hospital handover were assumed to have a hospital stay of zero 
days. Intensive care-free days was defined as the number of days that a patient was alive and not 
requiring intensive care during the first 30 days after the cardiac arrest. Hospital-free survival days 
was defined as the number of days alive post-hospital discharge during the first 30 days after the 
cardiac arrest. Re-admission to hospital or ICU was not counted. 
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Follow-up questionnaires. 
Patients who were alive and consented to long-term follow-up were contacted by letter at the relevant 
follow-up point.  Non-responders were sent a 2nd letter followed by a telephone call before being 
declared lost to follow-up.  Participants were asked to self-complete several patient-reported outcome 
measures including two generic measures of health-related quality of life (HRQoL) - Short-Form 12-
item Health Survey version 2 (SF-12v2)15 and the single item EuroQoL-Visual Analogue Scale (EQ-
VAS)16– and domain-specific measures of emotional well-being - Hospital Anxiety and Depression Scale 
(HADS), Mini-Mental State Examination (MMSE)17 and the PTSD Civilian Checklist (PTSD-CL)18. 
Questionnaires were returned by post to the trial co-ordinating centre at Warwick Clinical Trials Unit. 
Analysis 
Patients’ outcomes were compared by treatment arm, using fixed-effect logistic and linear 
regression models to obtain unadjusted and adjusted odds ratios (OR) or mean difference and 95% 
confidence intervals (CI). The pre-specified covariates used in the adjusted models were age, sex, 
response time (time interval from 999 call to arrival of the trial vehicle), bystander CPR, and initial 
rhythm. We attempted adjusting for the clustering design using multilevel logistic models (using the 
GLIMMIX procedure with logit link function based on the binomial distribution). Because of the 
extremely low survival rates in each cluster (vehicle), the multilevel models could not be fitted with 
the vehicle random effect since this effect was not estimable. For this reason, we assumed that the 
intra-cluster correlation coefficient was negligible (0.001) and ordinary logistic regressions were 
fitted. Analyses used complete cases only, with no imputation.  Intention to treat approach was used 
for all analyses, which were conducted in SAS v9.3 and v9.4 (Cary, NC, USA). 
 
Results 
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The trial ran between April 15, 2010, and June 10, 2013 (which included 12 months’ follow-up).  
During this time 4471 patients were enrolled of which 1652 were allocated to receive LUCAS and 
2819 manual chest compression of which 1099 and 1868 were transferred to hospital.  377 patients 
in the LUCAS arm and 658 patients in the manual chest compression survived the event (survived 
beyond hospital admission (figure 1).  Data linkage between Hospital Episode Statistics and those 
who survived to hospital admission was successful for 264, 70% (LUCAS) and 507, 77% (manual chest 
compression group) and ICNARC critical care, 147 ((LUCAS) and 260 (control).   
Hospital stay characteristics 
For patients who survived to hospital discharge, the unadjusted hospital length of stay was 19.7 
(LUCAS) and 14.5 (control) days, with an adjusted mean difference of 2.5 days (95% CI -4.9, 9.9).  For 
non-survivors, the unadjusted hospital length of stay was 0.7 days (LUCAS) and 0.6 days (control), 
with an adjusted mean difference of -0.01 day (-0.5, 0.5). The number of days alive and free from 
intensive care in the first 30 days was 1.8 and 2.1 respectively (adjusted mean difference -0.5 (-0.9, -
0.1)). Unadjusted hospital free survival days was 0.7 (LUCAS) and 1.0 (control) (adjusted mean 
difference -0.4 (-0.6, -0.1)).   
Intensive care stay characteristics 
Table 1 summarises key characteristics of the intensive care stay of patients with matched ICNARC 
records. The majority of patients had temperatures consistent with the application of targeted 
temperature management (TTM), although this should be interpreted with caution due to 
substantial missing data.  Overall survival was similar between arms (42.9% LUCAS, 41.5% control, 
aOR 1.1 (95%CI 0.7-1.8). Treatment was withdrawn in approximately one third in each arm.  Small 
number of patients underwent heart beating solid organ donation and non-heart beating solid organ 
donation.      
3 and 12 month questionnaire follow-up 
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The 3 and 12 month questionnaire follow up rates for patients surviving to 3 and 12 months were 
53.7% and 55.6% respectively. Table 2 reports the follow up rates according to CPC category.  
Follow-up rates were lower in those with worse neurological outcomes. 
 
At the three month follow-up (Table 3), SF-12 mental and physical component scores (MCS, PSC), 
and EQ-VAS scores were slightly lower in the LUCAS-2 group than the control group.  The confidence 
intervals for the adjusted differences crossed zero. 
At 12-month follow-up (Table 4), all of the results were in the same direction, but only the Mini 
mental state examination showed significant difference between treatment arms (95% confidence 
intervals excluded zero). 
 
 
Discussion 
 
This study evaluated longer term outcomes amongst participants in the cluster randomised 
PARAMEDIC trial. The study found no significant differences in intensive care outcomes when 
comparing manual and mechanical (LUCAS) CPR. However, hospital-free survival was slightly 
reduced in patients assigned to the LUCAS arm compared to those in the standard compression arm, 
after adjustment for covariates. At twelve months follow up, physical function (SF-12), global quality 
of life (EQ-VAS) and depression (Hospital Anxiety Depression Scale) was similar in patients in the 
LUCAS arm compared to standard chest compressions. Whilst cognitive function (mini-mental state 
examination) score was slightly worse (-1.5 (95% CI -2.6, -0.4) the difference fell below the threshold 
of a clinically important difference (3.72 points).19  
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Mechanical chest compression devices have been evaluated in five randomised controlled trials, 
which enrolled over 10,000 participants.20  Meta-analyses of these trials results found no advantage 
to mechanical chest compression in survival to discharge/30 days (average OR 0.89, 95% CI 0.77-
1.02) and survival with good neurological outcome (average OR 0.76, 95% CI 0.53-1.11).20 These 
findings informed the International Liaison Committee for Resuscitation, Consensus on Science and 
Treatment Recommendation which suggests against the routine use of automated mechanical chest 
compression devices to replace manual chest compressions.21 This study is the first of the 
mechanical chest compression device studies to explore the long-term outcomes and health related 
quality of life in this cohort of patients.  
Compared to the UK adult population norms,22 survivors at 12-months post-arrest have a 
significantly reduced quality of life across all HRQOL measures; this was particularly reduced for the 
SF-12 physical component scores where the reduction was greater than half a standard deviation, 
and hence of potential clinical relevance.23 This contrasts with reports of comparable levels of 
mental and physical health on the SF-12 at 12-months for Australian survivors of OHCA and the 
general population.24,25 Although SF-12 MCS scores for the current study are comparable with those 
of the Australian cohort, PCS scores are significantly reduced. Both physical and mental health scores 
are slightly reduced when compared to those reported in a Dutch cohort of survivors at 6-12 months 
post arrest.26 A similarly reduced quality of life in survivors, as assessed by the EQ-5D-3L index, has 
been previously reported for this cohort.7,27 When compared to the UK population norm, the 
reduction ranged between 0.07 and 0.09 in the manual CPR group and between 0.21 and 0.22 in the 
LUCAS-2 group (at 3 and 12-months respectively). A reduction greater than 0.18 is reported to be of 
clinical relevance.28  
These findings are consistent with the observation in the main PARAMEDIC trial of marginally worse 
neurological outcomes 3 months after cardiac arrest reported previously (Cerebral Performance 
Category 1-2, 5% LUCAS versus 6% control [adjusted OR 0.72 (0.52-0.99)])6,7. This finding was 
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unexpected although not unprecedented as the ASPIRE trial which studied the Autopulse mechanical 
chest compression device was terminated early due to worse neurological outcomes in the 
intervention group.29 Physiologically, mechanical chest compression devices provide consistent 
quality CPR.30 Animal31 and human studies 32 report improved cortico-cerebral perfusion and 
cerebral oxygenation.  A possible explanation includes interruptions to chest compressions caused 
by the time taken to deploy the device.  The manufacturer recommends a two-stage approach to 
device deployment.  Stage one involves deployment of the back plate. Manual CPR is then restarted 
prior to pausing to deploying the device, preparing the suction cup and starting mechanical CPR.  
Analysis of transthoracic impedance data suggests stage one takes approximately 9 seconds (inter-
quartile range 5.5–14.5) and stage two 32.5 seconds (inter-quartile range 25–61).33 With focused 
team training it possible to reduce the duration for deployment to 13 seconds.34 This is likely to be 
particularly important when, as seen in our study, the exposure of paramedics to cardiac arrest is 
low (approximately 2 arrests per year).6  
The concept of disease free survival (number of days alive during a specific time period, free from 
disease) has been used widely in studies enrolling critically ill patients.  Ventilator free days has 
become popular as an intermediate outcome in trials of treatments for the acute respiratory distress 
syndrome.35 Its use is favoured for the improved statistical efficiency of a continuous as opposed to a 
dichotomous (alive / dead) outcome 35 and its patient centredness.36 Nichol was one of the first to 
use hospital free survival in a large cluster randomised trial comparing continuous chest 
compressions with positive pressure ventilation to standard CPR.37  That study concluded no overall 
difference in survival  (9% compression only, 9.7% interrupted chest compression, difference, −0.7 % 
95% CI −1.5 to 0.1). A small difference in hospital free survival (−0.2 days; 95% CI, −0.3 to −0.1) was 
however observed.  The present trial also found a very small difference in hospital free survival, 
favouring manual chest compressions.  However it is likely this falls below the threshold of a 
clinically important difference.  There may be value in further research to gain a better 
understanding of the  characteristics, interpretation and statistical analysis of hospital free survival.38   
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Strengths of this study include the prospective, randomised design, its independence from 
commercial sponsorship39 and focus on long term outcomes.  Nevertheless, this and similar studies 
face limitations which require the results to be interpreted with caution.  All longer term follow-up 
studies are limited by the effects of survivor bias i.e. only those alive are eligible for inclusion in 
follow-up. This is further compounded in the present study, as those with the worse neurological 
outcomes were less likely to participate in follow-up (Table 2) which risks introducing outcome 
reporting bias.  Accepting these limitations, the overall follow-up rate amongst survivors was on 
average 55%. This is within the range of rates reported in other studies (range 25%-86% 40-42). These 
high levels of missing data risk underestimating or potentially misleading the full impact of cardiac 
arrest amongst survivors.   
 
Conclusion: 
 
There were no clinically important differences identified in outcomes at long term follow-up 
between  those allocated to the mechanical chest compression compared to those receiving manual 
chest compression.      
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Figure 1: CONSORT flow diagram showing follow-up rates by treatment arm 
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Table 1: Outcomes by treatment arm in patients with ICNARC data. 
 
  
LUCAS 
(N=147) 
Control (N=260) 
Odds ratio or 
Difference 
(95% CI); 
unadjusted 
Odds ratio or 
Difference (95% 
CI); adjusted* 
ICU survival     
Survived at ICU 63 (42.9%) 108 (41.5%) 1.1 (0.7, 1.6) 1.1 (0.7, 1.8) 
Deceased at ICU 84 (57.1%) 152 (58.5%) 1 1 
     
Length of stay days     
Mean (SD) 7.3 (20.3) 4.5 (5.1) 2.9 (0.3, 5.5) 3.4 (0.6, 6.3) 
Median (IQR) 3.0 (6.0) 3.0 (4.0)   
Missing 0 0   
     
Low central temperature less than 
34 degrees 
   
 
Yes 55 (37.4%) 80 (30.8%) 1.8 (0.8, 4.2) 2.1 (0.8, 5.6) 
No 9 (6.1%) 24 (9.2%) 1 1 
Missing 83 (56.5%) 156 (60.0%)   
     
Treatment withheld/withdrawn**     
Both withheld then withdrawn 10 (6.8%) 13 (5.0%) 1.3 (0.5, 3.0) 1.2 (0.5, 3.1) 
Withheld 2 (1.4%) 2 (0.8%)  1.6 (0.2, 11.8) 1.7 (0.2, 13.8) 
Withdrawn 41 (27.9%) 92 (35.4%) 0.7 (0.5, 1.1)  0.7 (0.4, 1.1) 
Neither 94 (63.9%) 153 (58.8%) 1  1 
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Organ donation     
Heartbeating solid organ donor 7 (4.8%) 6 (2.3%) 2.2 (0.7, 6.6) 4.0 (1.0,15.2) 
Non-heartbeating solid organ 
donor 
6 (4.1%) 9 (3.5%) 1.2 (0.4, 3.6) 1.2 (0.4, 4.0) 
Tissue donor only 1 (0.7%) 7 (2.7%) 0.3 (<0.1, 2.2) 0.4 (<0.1, 3.1) 
No solid organs or tissues 
donated 
70 (47.6%) 129 (49.6%) 1 1 
Missing 63 (42.9%) 109 (41.9%)   
 
Note: *: Odds ratio and mean difference are adjusted for age, sex, rhythm, bystander CPR and 
response time; ** Withholding treatment is defined as a decision not to start or increase a life-
sustaining intervention and withdrawing treatment as a decision to actively stop a life-sustaining 
intervention that is presently being given.  
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Table 2: 3 and 12 month questionnaire follow-up rates 
 
 LUCAS Manual chest compression 
3 month CPC 
categories 
 
CPC 1 CPC 2 CPC 3 CPC 4 CPC 1 CPC 2 CPC 3 CPC 4 
Number alive 
at 3 months 
 
67 10 14 2 153 15 10 1 
3 month 
questionnaire 
response 
55.2% 50.0% 28.6% 50.0% 61.4% 26.7% 10.0% 0.0% 
Alive at 12 
months* 
64 
(95.5%) 
10 
(100.0%) 
11 
(78.6%) 
1 
(50.0%) 
148 
(96.7%) 
13 
(96.7%) 
9 
(90.0%) 
1 
(100.0%) 
12 month 
questionnaire 
response 
60.9% 60.0% 27.3 % 0.0% 60.1% 30.8% 20.0% 0.0% 
Note: * percentage is calculated as number of alive at 12 months/number of alive at 3 months. 
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Table 3 Outcome at 3 months for the SF-12v2 and EQ-VAS.  
Patient-reported outcomesa LUCAS-2  
n=47 
CONTROL   
N=99 
Difference 
(95% CI); 
unadjusted 
Difference 
(95% CI); 
adjusted* 
Generic health-related quality of life 
SF-12 PCS Mean (SD)   38.9 (11.5)   41.7 (10.9) -2.8 (-6.7, 
1.1) 
-3.0 (-7.0, 1.1) 
Median (IQR)   40.8 (32.1, 
48.0) 
  42.6 (34.7, 
49.4) 
  
missing 2 2   
SF-12 MCS 
 
Mean (SD) 47.3 (13.4) 48.9 (10.5) -1.6 (-5.6, 
2.5) 
-1.5 (-5.5, 2.6) 
Median (IQR) 51.7 (38.2, 
57.3) 
50.2 (42.1, 
57.2) 
  
missing 2 2   
EQ-VAS Mean (SD) 63.8 (23.5) 72.0 (18.0) -8.2 (-15.1, -
1.3) 
-6.8 (-13.7, 
0.1) 
Median (IQR) 65.0 (50.0, 
80.0) 
75.0 (64.0, 
85.0) 
  
missing 0 0   
Note: *: Mean difference are adjusted for age, sex, rhythm, bystander CPR and response time. 
Footnote:  
a SF-12 Physical Component Score (PCS) and Mental Component Scores (MCS) are scored 0-100; higher scores represent 
better health states. The UK adult population mean or normative value is 50 (SD 10) for both PCS and MCS [Layte and 
Jenkinson, 2001)  (https://campaign.optum.com/optum-outcomes/what-we-do/health-
surveys.html?gclid=CLGxgvym9tACFU-T7QodWoQHkg). 
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EQ-VAS is scored 0 to 100, where 100 represents the best quality of life. The UK adult population mean or normative 
value is 82.48 (0.292) for the EQ-VAS. 
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Table 4 Patient-reported outcomes at 12 months for- the SF-12v2, EQ-VAS and MMSE. 
Patient-reported outcomesa LUCAS-2   
N=48 
CONTROL   
N= 95 
Difference (95% 
CI); unadjusted 
Difference (95% 
CI); adjusted* 
Generic health-related quality of life 
SF-12 PCS Mean (SD) 40.1 (12.7) 43.8 (10.7) -3.8 (-7.8, 0.2) -3.5 (-7.4, 0.4) 
Median (IQR) 40.7 (30.8, 
51.0) 
44.9 (36.1, 
52.5) 
  
missing 1 2   
SF-12 MCS 
 
Mean (SD) 47.5 (11.5) 49.4 (11.8) -1.8 (-5.9, 2.3) -1.5 (-5.5, 2.5) 
Median (IQR) 48.9 (42.9, 
55.3) 
50.8 (42.7, 
59.1) 
  
missing 1 2   
EQ-VAS Mean (SD) 68.3 (22.0) 75.0 (17.4) -6.7 (-13.3, -0.07) -6.4 (-13.1, 0.3) 
Median (IQR) 72.0 (54.5, 
87.5) 
80.0 (64.0, 
90.0) 
  
missing 0 0   
Cognitive function 
Mini mental state 
examination 
Mean (SD) 26.9 (3.7) 28.0 (2.3) -1.12 (-2.2, -0.08) -1.5 (-2.6, -0.4) 
 Median (IQR) 28.0 (27.0, 
29.0) 
29.0 (27.0, 
30.0) 
  
 missing 1 1   
Emotional well-being 
HADS: anxiety Mean (SD) 6.7 (4.8) 5.7 (4.2) 0.9 (-0.6, 2.5) 0.6 (-0.9, 2.1) 
 Median (IQR) 6.0 (3.0, 10.0) 6.0 (2.0, 8.0)   
 missing 0 0   
HADS: depression Mean (SD) 5.8 (4.4) 4.4 (3.5) 1.42 (0.09, 2.8) 1.1 (-0.2, 2.5) 
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 Median (IQR) 5.0 (2.0, 9.0) 4.0 (1.0, 7.0)   
 missing 0 0   
PTSD-CL Mean (SD) 32.0 (12.9) 30.2 (11.0) 1.8 (-2.4, 5.9) 1.6 (-2.6, 5.7) 
 Median (IQR) 28.0 (22.0, 
36.0) 
28.0 (20.0, 
38.0) 
  
 missing 3 2   
Note: *: Mean difference are adjusted for age, sex, rhythm, bystander CPR and time interval from 
999 call to arrival of the trial vehicle. 
Footnote:  
a SF-12 Physical Component Score (PCS) and Mental Component Scores (MCS) are scored 0-100; higher scores represent 
better health states. The UK adult population mean or normative value is 50 (SD 10) for both PCS and MCS [Layte and 
Jenkinson, 2001)  (https://campaign.optum.com/optum-outcomes/what-we-do/health-
surveys.html?gclid=CLGxgvym9tACFU-T7QodWoQHkg). 
EQ-VAS is scored 0 to 100, where 100 represents the best quality of life. The UK adult population mean or normative 
value is 82.48 (0.292) for the EQ-VAS (Kind et al, 1999a,b). 
MMSE is scored 0-30, where higher scores represent better health. 
HADS – Anxiety and Depression Scales are scored 0-21, where lower scores represent better levels of health.  
PTSD-CL is scored 17-85, where lower scores represent better levels of health.  
